vs
InnovAge Holding Corp.（INNV）与Strata Critical Medical, Inc.（SRTA）财务数据对比。点击上方公司名可切换其他公司
InnovAge Holding Corp.的季度营收约是Strata Critical Medical, Inc.的10.5倍（$239.7M vs $22.7M）。Strata Critical Medical, Inc.同比增速更快（361.2% vs 14.7%）。InnovAge Holding Corp.自由现金流更多（$19.0M vs $-10.2M）。过去两年InnovAge Holding Corp.的营收复合增速更高（11.4% vs -33.6%）
InnovAge Holding Corp是美国领先的老年护理服务商，主要运营老年人全包护理项目（PACE），为符合条件的高龄群体提供综合医疗、社会支持与日常生活协助，帮助老人居家养老，服务覆盖美国多个州。
Strata Critical Medical, Inc.是一家医疗技术企业，设计、生产及销售用于重症监护、麻醉及外科场景的一次性医疗用品，主要服务北美及部分欧洲地区的医疗机构，专注提升患者安全与临床诊疗效率。
INNV vs SRTA — 直观对比
营收规模更大
INNV
是对方的10.5倍
$22.7M
营收增速更快
SRTA
高出346.5%
14.7%
自由现金流更多
INNV
多$29.2M
$-10.2M
两年增速更快
INNV
近两年复合增速
-33.6%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $239.7M | $22.7M |
| 净利润 | $10.6M | — |
| 毛利率 | 22.0% | -0.9% |
| 营业利润率 | 5.5% | -18.4% |
| 净利率 | 4.4% | — |
| 营收同比 | 14.7% | 361.2% |
| 净利润同比 | 180.3% | — |
| 每股收益（稀释后） | $0.08 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INNVSRTA
| Q4 25 | $239.7M | $22.7M | ||
| Q3 25 | $236.1M | $49.3M | ||
| Q2 25 | $221.4M | $70.8M | ||
| Q1 25 | $218.1M | $54.3M | ||
| Q4 24 | $209.0M | $-8.7M | ||
| Q3 24 | $205.1M | $36.1M | ||
| Q2 24 | $199.4M | $67.9M | ||
| Q1 24 | $193.1M | $51.5M |
净利润INNVSRTA
| Q4 25 | $10.6M | — | ||
| Q3 25 | $8.0M | $57.4M | ||
| Q2 25 | $-785.0K | $-3.7M | ||
| Q1 25 | $-11.4M | $-3.5M | ||
| Q4 24 | $-13.2M | — | ||
| Q3 24 | $-4.9M | $-2.0M | ||
| Q2 24 | $-1.7M | $-11.3M | ||
| Q1 24 | $-5.9M | $-4.2M |
毛利率INNVSRTA
| Q4 25 | 22.0% | -0.9% | ||
| Q3 25 | 21.8% | 23.6% | ||
| Q2 25 | 18.6% | 25.1% | ||
| Q1 25 | 18.7% | 22.1% | ||
| Q4 24 | 17.7% | — | ||
| Q3 24 | 16.8% | 20.8% | ||
| Q2 24 | 18.3% | 24.1% | ||
| Q1 24 | 17.6% | 19.7% |
营业利润率INNVSRTA
| Q4 25 | 5.5% | -18.4% | ||
| Q3 25 | 3.5% | -11.4% | ||
| Q2 25 | -1.0% | -7.0% | ||
| Q1 25 | -4.7% | -14.0% | ||
| Q4 24 | -6.0% | — | ||
| Q3 24 | -2.4% | -19.7% | ||
| Q2 24 | -2.4% | -17.9% | ||
| Q1 24 | -3.0% | -19.2% |
净利率INNVSRTA
| Q4 25 | 4.4% | — | ||
| Q3 25 | 3.4% | 116.5% | ||
| Q2 25 | -0.4% | -5.3% | ||
| Q1 25 | -5.2% | -6.4% | ||
| Q4 24 | -6.3% | — | ||
| Q3 24 | -2.4% | -5.4% | ||
| Q2 24 | -0.9% | -16.7% | ||
| Q1 24 | -3.0% | -8.2% |
每股收益（稀释后）INNVSRTA
| Q4 25 | $0.08 | $-0.11 | ||
| Q3 25 | $0.06 | $0.70 | ||
| Q2 25 | $0.00 | $-0.05 | ||
| Q1 25 | $-0.08 | $-0.04 | ||
| Q4 24 | $-0.10 | $-0.11 | ||
| Q3 24 | $-0.04 | $-0.03 | ||
| Q2 24 | $-0.01 | $-0.15 | ||
| Q1 24 | $-0.04 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $126.0M | $31.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $256.8M | $279.1M |
| 总资产 | $527.5M | $325.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资INNVSRTA
| Q4 25 | $126.0M | $31.0M | ||
| Q3 25 | $109.4M | $22.8M | ||
| Q2 25 | $105.9M | $58.8M | ||
| Q1 25 | $101.7M | $34.8M | ||
| Q4 24 | $86.9M | $18.4M | ||
| Q3 24 | $85.7M | $20.0M | ||
| Q2 24 | $102.8M | $26.3M | ||
| Q1 24 | $99.3M | $36.8M |
总债务INNVSRTA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $60.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $66.0M | — | ||
| Q1 24 | — | — |
股东权益INNVSRTA
| Q4 25 | $256.8M | $279.1M | ||
| Q3 25 | $245.0M | $283.0M | ||
| Q2 25 | $235.0M | $223.1M | ||
| Q1 25 | $238.0M | $219.7M | ||
| Q4 24 | $248.5M | $221.9M | ||
| Q3 24 | $260.9M | $233.5M | ||
| Q2 24 | $269.3M | $229.4M | ||
| Q1 24 | $281.1M | $236.6M |
总资产INNVSRTA
| Q4 25 | $527.5M | $325.5M | ||
| Q3 25 | $510.2M | $335.1M | ||
| Q2 25 | $526.9M | $257.9M | ||
| Q1 25 | $536.6M | $250.6M | ||
| Q4 24 | $524.8M | $256.7M | ||
| Q3 24 | $527.7M | $282.9M | ||
| Q2 24 | $547.7M | $280.3M | ||
| Q1 24 | $527.4M | $282.8M |
负债/权益比INNVSRTA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.26× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.25× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.4M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | $19.0M | $-10.2M |
| 自由现金流率自由现金流/营收 | 7.9% | -44.7% |
| 资本支出强度资本支出/营收 | 1.0% | 8.1% |
| 现金转化率经营现金流/净利润 | 2.01× | — |
| 过去12个月自由现金流最近4个季度 | $49.4M | $-58.5M |
8季度趋势，按日历期对齐
经营现金流INNVSRTA
| Q4 25 | $21.4M | $-8.3M | ||
| Q3 25 | $3.9M | $-37.3M | ||
| Q2 25 | $9.0M | $-3.1M | ||
| Q1 25 | $24.6M | $-246.0K | ||
| Q4 24 | $6.8M | $-1.8M | ||
| Q3 24 | $-7.5M | $6.4M | ||
| Q2 24 | $1.9M | $8.4M | ||
| Q1 24 | $3.5M | $-15.6M |
自由现金流INNVSRTA
| Q4 25 | $19.0M | $-10.2M | ||
| Q3 25 | $-153.0K | $-40.1M | ||
| Q2 25 | $8.8M | $-5.4M | ||
| Q1 25 | $21.7M | $-2.9M | ||
| Q4 24 | $5.4M | $-6.3M | ||
| Q3 24 | $-9.7M | $-3.0M | ||
| Q2 24 | $-1.4M | $-7.7M | ||
| Q1 24 | $3.1M | $-16.4M |
自由现金流率INNVSRTA
| Q4 25 | 7.9% | -44.7% | ||
| Q3 25 | -0.1% | -81.4% | ||
| Q2 25 | 4.0% | -7.6% | ||
| Q1 25 | 10.0% | -5.3% | ||
| Q4 24 | 2.6% | 72.7% | ||
| Q3 24 | -4.7% | -8.2% | ||
| Q2 24 | -0.7% | -11.4% | ||
| Q1 24 | 1.6% | -31.8% |
资本支出强度INNVSRTA
| Q4 25 | 1.0% | 8.1% | ||
| Q3 25 | 1.7% | 5.7% | ||
| Q2 25 | 0.1% | 3.2% | ||
| Q1 25 | 1.3% | 4.8% | ||
| Q4 24 | 0.6% | -52.6% | ||
| Q3 24 | 1.1% | 25.8% | ||
| Q2 24 | 1.7% | 23.8% | ||
| Q1 24 | 0.2% | 1.6% |
现金转化率INNVSRTA
| Q4 25 | 2.01× | — | ||
| Q3 25 | 0.49× | -0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INNV
暂无分部数据
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
